Jfs Wealth Advisors, LLC Sage Therapeutics, Inc. Transaction History

Jfs Wealth Advisors, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 07, 2024	SELL	$17.1 - $22.26 $85 - $111	-5 Reduced 38.46%	8 $0
Q3 2023 Nov 02, 2023	SELL	$16.75 - $48.98 $67 - $195	-4 Reduced 23.53%	13 $0
Q2 2023 Aug 07, 2023	BUY	$40.65 - $59.54 $121 - $178	3 Added 21.43%	17 $0
Q1 2023 Apr 19, 2023	BUY	$37.27 - $46.57 $74 - $93	2 Added 16.67%	14 $0
Q4 2022 Feb 13, 2023	SELL	$32.2 - $43.61 $32 - $43	-1 Reduced 7.69%	12 $0
Q3 2022 Oct 21, 2022	BUY	$32.28 - $43.27 $96 - $129	3 Added 30.0%	13 $1,000
Q2 2022 Aug 02, 2022	BUY	$27.52 - $37.99 $82 - $113	3 Added 42.86%	10 $0
Q1 2022 May 02, 2022	BUY	$30.71 - $45.71 $122 - $182	4 Added 133.33%	7 $0
Q4 2021 Feb 03, 2022	BUY	$37.06 - $47.11 $111 - $141	3 New	3 $0

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $326M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Jfs Wealth Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Jfs Wealth Advisors, LLC with notifications on news.